FLUICELL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.091 SEK | -5.21% |
|
-3.19% | -85.60% |
| 08/03 | Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 08/03 | Fluicell AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 3.25M 301K 25.08M | Sales 2023 | 3.34M 309K 25.75M | Capitalization | 17.2M 1.59M 133M |
|---|---|---|---|---|---|
| Net income 2022 | -21M -1.94M -162M | Net income 2023 | -26M -2.4M -201M | EV / Sales 2022 | 4.2 x |
| Net cash position 2022 | 24.46M 2.26M 189M | Net cash position 2023 | 2.76M 255K 21.31M | EV / Sales 2023 | 4.33 x |
| P/E ratio 2022 |
-1.89
x | P/E ratio 2023 |
-0.62
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.21% | ||
| 1 week | -3.19% | ||
| Current month | +2.71% | ||
| 1 month | -24.17% | ||
| 3 months | -82.80% | ||
| 6 months | -91.18% | ||
| Current year | -85.60% |
1 week
0.09
0.10
1 month
0.090.14
Current year
0.091.00
1 year
0.092.50
3 years
0.0934.70
5 years
0.0943.80
10 years
0.0943.80
| Managers | Title | Age | Since |
|---|---|---|---|
Carolina Trkulja
CEO | Chief Executive Officer | 40 | - |
| Founder | 44 | 02/12/02 | |
| Director of Finance/CFO | 54 | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Orwar
BRD | Director/Board Member | 60 | 01/15/01 |
Daniel T. Chiu
BRD | Director/Board Member | 52 | 01/17/01 |
Stefan Tilk
CHM | Chairman | 59 | 01/16/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 0.091 | -5.21% | 2,530,367 |
| 02/24/02 | 0.096 | +8.35% | 4,157,315 |
| 30/24/30 | 0.0886 | -7.90% | 2,041,821 |
| 29/24/29 | 0.0962 | +2.34% | 2,840,920 |
| 26/24/26 | 0.094 | +3.52% | 4,836,634 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 08:54 pm IST
More quotes
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâs products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Calendar
10/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -85.60% | 2.77M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- FLUI Stock
